American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Cadence Design Systems (NASDAQ:CDNS) Price Target Lowered to $318.00 at Piper Sandler

Cadence Design Systems (NASDAQ:CDNS) Price Target Lowered to $318.00 at Piper Sandler

Cadence Design Systems (NASDAQ:CDNS – Free Report) had its price target reduced by Piper Sandler from $334.00 to $318.00 in a research note published on Tuesday, Benzinga reports. Piper Sandler currently has a neutral rating... More of this article »
Image about Capital Bancorp (NASDAQ:CBNK) Price Target Cut to $26.00 by Analysts at Hovde Group

Capital Bancorp (NASDAQ:CBNK) Price Target Cut to $26.00 by Analysts at Hovde Group

Capital Bancorp (NASDAQ:CBNK – Free Report) had its price target decreased by Hovde Group from $27.00 to $26.00 in a research report released on Tuesday, MarketBeat Ratings reports. Hovde Group currently has an outperform rating... More of this article »
Image about Cathay General Bancorp (NASDAQ:CATY) Price Target Lowered to $41.00 at Keefe, Bruyette & Woods

Cathay General Bancorp (NASDAQ:CATY) Price Target Lowered to $41.00 at Keefe, Bruyette & Woods

Cathay General Bancorp (NASDAQ:CATY – Free Report) had its target price cut by Keefe, Bruyette & Woods from $46.00 to $41.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have... More of this article »
Image about Maplebear (NASDAQ:CART) Given Hold Rating at Needham & Company LLC

Maplebear (NASDAQ:CART) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Maplebear (NASDAQ:CART – Free Report) in a research report report published on Tuesday morning, Benzinga reports. A number of other analysts also recently... More of this article »
Image about BioXcel Therapeutics’ (BTAI) Buy Rating Reaffirmed at HC Wainwright

BioXcel Therapeutics’ (BTAI) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the... More of this article »
Image about Beam Global’s (BEEM) Buy Rating Reaffirmed at Roth Mkm

Beam Global’s (BEEM) Buy Rating Reaffirmed at Roth Mkm

Roth Mkm restated their buy rating on shares of Beam Global (NASDAQ:BEEM – Free Report) in a research note published on Tuesday morning, Benzinga reports. Roth Mkm currently has a $9.00 price target on the stock. Several other... More of this article »
Image about Beam Therapeutics (NASDAQ:BEAM) Receives Outperform Rating from Wedbush

Beam Therapeutics (NASDAQ:BEAM) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $57.00 price objective on the stock. Several... More of this article »
Image about Mastercard Incorporated (NYSE:MA) Major Shareholder Foundation Mastercard Sells 109,000 Shares of Stock

Mastercard Incorporated (NYSE:MA) Major Shareholder Foundation Mastercard Sells 109,000 Shares of Stock

Mastercard Incorporated (NYSE:MA – Get Free Report) major shareholder Foundation Mastercard sold 109,000 shares of Mastercard stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price... More of this article »
Image about T-Mobile US, Inc. (NASDAQ:TMUS) Director Telekom Ag Deutsche Sells 189,670 Shares

T-Mobile US, Inc. (NASDAQ:TMUS) Director Telekom Ag Deutsche Sells 189,670 Shares

T-Mobile US, Inc. (NASDAQ:TMUS – Get Free Report) Director Telekom Ag Deutsche sold 189,670 shares of the stock in a transaction on Friday, April 19th. The stock was sold at an average price of $161.87, for a total value of $30,701,882.90.... More of this article »
Image about BCB Bancorp (NASDAQ:BCBP) Price Target Cut to $12.00 by Analysts at Keefe, Bruyette & Woods

BCB Bancorp (NASDAQ:BCBP) Price Target Cut to $12.00 by Analysts at Keefe, Bruyette & Woods

BCB Bancorp (NASDAQ:BCBP – Free Report) had its price target cut by Keefe, Bruyette & Woods from $14.00 to $12.00 in a research report report published on Tuesday, Benzinga reports. They currently have a market perform rating... More of this article »
Image about Delta Air Lines, Inc. (NYSE:DAL) President Glen W. Hauenstein Sells 100,000 Shares

Delta Air Lines, Inc. (NYSE:DAL) President Glen W. Hauenstein Sells 100,000 Shares

Delta Air Lines, Inc. (NYSE:DAL – Get Free Report) President Glen W. Hauenstein sold 100,000 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $49.05, for a total value... More of this article »
Image about Paramount Group (PGRE) Scheduled to Post Earnings on Wednesday

Paramount Group (PGRE) Scheduled to Post Earnings on Wednesday

Paramount Group (NYSE:PGRE – Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, May 1st. Analysts expect Paramount Group to post earnings of $0.20 per share for the quarter.... More of this article »
Image about Affirm (NASDAQ:AFRM) Receives “Hold” Rating from Needham & Company LLC

Affirm (NASDAQ:AFRM) Receives “Hold” Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Affirm (NASDAQ:AFRM – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. A number of other equities analysts also recently commented... More of this article »
Image about AGNC Investment (NASDAQ:AGNC) Price Target Lowered to $10.25 at Jonestrading

AGNC Investment (NASDAQ:AGNC) Price Target Lowered to $10.25 at Jonestrading

AGNC Investment (NASDAQ:AGNC – Free Report) had its price objective lowered by Jonestrading from $10.75 to $10.25 in a report issued on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the real estate... More of this article »
Image about Adicet Bio (NASDAQ:ACET) Receives “Outperform” Rating from Wedbush

Adicet Bio (NASDAQ:ACET) Receives “Outperform” Rating from Wedbush

Wedbush restated their outperform rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $5.00 price objective on the stock. ACET... More of this article »